Brief: Oncternal Therapeutics Receives IND Clearance For Drug Candidate Onct-808
03/10/2022 21:49
Oct 3 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS RECEIVES IND CLEARANCE FOR
ONCT-808, ITS
AUTOLOGOUS CAR T PRODUCT CANDIDATE TARGETING ROR1 FOR THE
TREATMENT OF AGGRESSIVE B CELL LYMPHOMA
Source text for Eikon: ID:nGNX2Ywrf7
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;